Grade-3 and grade-4 infusion-related adverse events and liver function test abnormalities by treatment dose
. | Treatment dose . | . | . | . | ||
|---|---|---|---|---|---|---|
| Adverse event or abnormality . | 6 mg/m2, n = 14 . | 7.5 mg/m2, n = 2 . | 9 mg/m2, n = 13 . | Total . | ||
| Adverse event | ||||||
| Systemic | 4 | 1 | 3 | 8 | ||
| Chills | 0 | 0 | 1 | 1 | ||
| Fever | 2 | 0 | 1 | 3 | ||
| Cardiovascular system, hypotension | 0 | 0 | 1 | 1 | ||
| Digestive system | ||||||
| Anorexia | 0 | 1 | 0 | 1 | ||
| Nausea | 0 | 1 | 0 | 1 | ||
| Hematologic and lymphatic systems | ||||||
| Leukopenia | 2 | 0 | 0 | 2 | ||
| Thrombocytopenia | 2 | 0 | 0 | 2 | ||
| Nervous system, tremor | 0 | 0 | 1 | 1 | ||
| Liver function test abnormality | ||||||
| ALT | 2 | 0 | 1 | 3 | ||
| AST | 1 | 0 | 2 | 3 | ||
| Total bilirubin | 1 | 0 | 1 | 2 | ||
. | Treatment dose . | . | . | . | ||
|---|---|---|---|---|---|---|
| Adverse event or abnormality . | 6 mg/m2, n = 14 . | 7.5 mg/m2, n = 2 . | 9 mg/m2, n = 13 . | Total . | ||
| Adverse event | ||||||
| Systemic | 4 | 1 | 3 | 8 | ||
| Chills | 0 | 0 | 1 | 1 | ||
| Fever | 2 | 0 | 1 | 3 | ||
| Cardiovascular system, hypotension | 0 | 0 | 1 | 1 | ||
| Digestive system | ||||||
| Anorexia | 0 | 1 | 0 | 1 | ||
| Nausea | 0 | 1 | 0 | 1 | ||
| Hematologic and lymphatic systems | ||||||
| Leukopenia | 2 | 0 | 0 | 2 | ||
| Thrombocytopenia | 2 | 0 | 0 | 2 | ||
| Nervous system, tremor | 0 | 0 | 1 | 1 | ||
| Liver function test abnormality | ||||||
| ALT | 2 | 0 | 1 | 3 | ||
| AST | 1 | 0 | 2 | 3 | ||
| Total bilirubin | 1 | 0 | 1 | 2 | ||